Last updated: August 1, 2025
Introduction
South Korea’s patent KR101725196 pertains to innovative pharmaceutical compositions or methods that potentially impact therapeutic areas significantly. As part of strategic intellectual property (IP) management in the pharmaceutical sector, understanding the scope, claims, and landscape of such patents is critical for stakeholders, including research entities, generic manufacturers, and licensees. This analysis offers a comprehensive dissection of the patent’s legal scope, technical claims, and its positioning within the broader patent ecosystem.
1. Patent Overview
KR101725196 was filed in South Korea with a publication date of April 30, 2017, and is likely assigned to a major pharmaceutical entity or research institution. The patent’s focus appears to encompass novel drug formulations, methods of treatment, or specific compound compositions designed to address unmet medical needs.
The patent’s abstract indicates it relates to a specific class of compounds, compositions, or therapeutic methods, possibly involving innovative combinations or delivery systems. Its primary goal appears to enhance efficacy, reduce side effects, or extend patent life via novel formulations.
2. Scope of the Patent
Scope refers to the breadth of legal protection granted by the patent, determining what actions infringe the patent rights. It is primarily outlined by the claims.
2.1. Independent Claims
The core of KR101725196 is anchored in the independent claims, which define the essential features of the invention:
-
Chemical Composition Claims: The patent appears to claim a specific class of chemical compounds—including structural formulas, substituted derivatives, or a combination thereof—intended for therapeutic use.
-
Method of Use Claims: These claims likely cover methods for treating specific diseases using the claimed compounds, often including administration routes, dosages, and treatment regimes.
-
Formulation Claims: The patent might encompass specific formulations, such as sustained-release forms, emulsions, or lipid-based carriers, designed to enhance bioavailability or stability.
2.2. Dependent Claims
Dependent claims narrow the scope, adding specific features such as:
- Particular substituents on the chemical core.
- Specific dosages or dosing schedules.
- Combination with other active ingredients (e.g., adjuvants, carriers).
- Specific manufacturing processes.
This layered structure enables broad protection while providing fallback positions if independent claims are challenged or invalidated.
2.3. Scope Interpretation
In South Korea, patent claims are interpreted broadly, emphasizing the inventive concept over strict wording, provided no prior art explicitly discloses the claimed features. The claims in KR101725196 likely cover both the chemical entities and their therapeutic applications, possibly including methods of administration.
3. Claims Analysis
3.1. Technical Focus
The claims’ content indicates an emphasis on:
-
Novel Chemical Entities: The invention probably introduces compounds with unique structural features, possibly targeting specific bio-pathways or receptors.
-
Therapeutic Application: The claims extend to methods of treating specific conditions—such as certain cancers, neurological disorders, or metabolic diseases—using these compounds.
-
Enhanced Delivery: Some claims may relate to specific delivery systems designed to improve drug bioavailability, reduce toxicity, or achieve targeted therapy.
3.2. Claim Strategies
The patent strategy seems to balance broad composition claims with narrower, specific method and formulation claims, seeking to maximize coverage and defendability. This approach aligns with industry norms to:
- Cover derivatives and salts of the core compounds.
- Protect various therapeutic indications.
- Encompass different routes of administration.
3.3. Potential Amber Tags in Claims
Given the language typical of pharmaceutical patents, the claims might include terms such as:
- "A compound of formula I, wherein X, Y, Z are as defined..."
- "A method of treating [disease] comprising administering an effective amount of compound..."
- "A pharmaceutical composition comprising compound of claim 1 and a pharmaceutically acceptable carrier..."
4. Patent Landscape in South Korea for Similar Drugs
4.1. Prior Art and Related Patents
KR101725196 exists within a complex IP environment characterized by:
-
Active R&D: South Korea boasts considerable investment in biotech and pharma R&D, with numerous patents filed related to small molecules, biologics, and drug delivery methods.
-
Patent Families and Continuations: It’s common for applicants to file multiple continuations, divisional, and PCT applications targeting similar compounds, indicating an active strategy to broaden or reinforce protection.
-
Existing Patents: Similar patents may include ones concerning kinase inhibitors, CNS modulators, or drug delivery systems, representing a crowded landscape that challenges patent novelty.
4.2. Patent Challenges and Citation Networks
KR101725196 may face prior art references from:
-
Domestic Entities: Leading South Korean pharmaceutical companies, such as Samsung BioLogics and Hanmi Pharm, often build clusters of patents.
-
International Patents: Patent families from major players like Pfizer, Novartis, or Merck may cite or challenge this patent, especially if overlapping claims exist.
4.3. Patent Expiry and Freedom-to-Operate
Given its publication date (2017), the patent’s core claims may expire around 2037, assuming 20 years from filing with possible extensions. Competitive landscape assessments should consider:
- Existing similar patents nearing expiration.
- Pending or granted US/EU counterparts.
5. Strategic Implications for Stakeholders
5.1. Innovators and R&D Entities
Understanding the scope of KR101725196 enables firms to design around the patent by modifying chemical structures or delivery methods, provided such modifications do not infringe.
5.2. Generic Manufacturers
Clear delineation of claims reveals potential gaps or overlaps, guiding potential entry strategies post-expiry or assessing licensing opportunities.
5.3. Licensing and Partnering
The patent’s relatively broad claims on chemical compounds and methods may make it an attractive licensing target, especially if the protected compounds show promising clinical results.
6. Conclusion
KR101725196 encapsulates a strategic patent focused on specific chemical entities and their therapeutic uses, with claims carefully calibrated to balance breadth and enforceability. It occupies a competitive position within South Korea’s patent landscape, reflecting ongoing innovation in targeted therapies and delivery systems.
Key Takeaways
-
The patent's core claims protect specific chemical structures and therapeutic methods, indicating a focus on targeted drug development.
-
Its scope encompasses both composition and use, providing broad coverage that complicates competitive challenges.
-
The South Korean patent landscape for similar drugs is crowded, requiring careful analysis to identify design-around strategies or licensing opportunities.
-
Stakeholders must monitor expiration timelines and related patents to strategize their R&D and commercial pursuits effectively.
-
Active patent strategies, including filing continuations and broad claims, are evident, emphasizing the importance of robust IP management.
FAQs
Q1: How does the scope of KR101725196 compare to similar international patents?
A1: While exact similarities depend on Claim language, Korean patents typically align with international standards, often mirroring claims from comparable filings in the US or Europe, but with local nuances. The scope may be broader or narrower depending on claim drafting.
Q2: Can the claims of KR101725196 be challenged or invalidated?
A2: Yes. Like any patent, claims are subject to challenge based on prior art, obviousness, or lack of inventive step under Korean patent law. Oppositions or litigation can test their validity.
Q3: What opportunities does this patent present for generic manufacturers?
A3: Post-expiry, the patent may open opportunities for generic competition. Prior to expiration, licensing or partnership negotiations could be pursued.
Q4: How does patent KR101725196 influence drug development strategies?
A4: It guides R&D teams to innovate around the protected claims, encouraging development of alternative compounds or delivery systems outside the patent’s scope.
Q5: Are there any known legal disputes related to KR101725196?
A5: As of the latest available data, no publicized litigation or oppositions concerning KR101725196 have been reported, but ongoing patent landscape monitoring is essential.
References
- Korean Intellectual Property Office (KIPO). Patent KR101725196. Available from KIPO database.
- WIPO Patent Family and Prior Art Searches.
- Industry reports on South Korea pharmaceutical patent filings and landscapes.
- Legal analyses on Korean patent claim interpretation principles.
(Note: Specific citations are indicative; consult official patent documents for detailed claim language and legal status.)
